Data updated: Mar 10, 2026
VELTASSA
PATIROMER SORBITEX CALCIUM
Approved 2015-10-21
3
Indications
--
Phase 3 Trials
10
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2015-10-21
- Routes
- ORAL
- Dosage Forms
- POWDER
VELTASSA Approval History
Loading approval history...
What VELTASSA Treats
3 FDA approvalsOriginally approved for its first indication in 2015 . Covers 3 distinct patient populations.
- Other (3)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VELTASSA FDA Label Details
ProVELTASSA Patents & Exclusivity
Latest Patent: Oct 2033
Exclusivity: Oct 2026
Patents (112 active)
Exclusivity
NPP
Until Oct 2026
NPP
Until Oct 2026
NPP
Until Oct 2026
NS
Until Oct 2026
NPP
Until Oct 2026
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.